PPHM

Peregrine Pharmaceuticals Announces Partial Exercise of Overallotment Option in Connection With Preferred Stock Offering

[Marketwired] – Peregrine Pharmaceuticals, Inc. , announced today that the underwriters of its underwritten public offering of its 10.50% Series E Convertible Preferred Stock have partially exercised their option to cover … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboardSee who Peregrine is hiring next, click here to view […]

PEREGRINE PHARMACEUTICALS INC Financials

moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboardSee who Peregrine is hiring next, click here to view […]

Peregrine Pharmaceuticals Announces Upcoming Events

[Marketwired] – Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that the company will participate … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboardSee who Peregrine is hiring next, click here to view […]

The Race For A Cure For Cancer, The Final Chapter

moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboardSee who Peregrine is hiring next, click here to view […]

Peregrine Pharmaceuticals Announces Closing of Preferred Stock Offering

[Marketwired] – Peregrine Pharmaceuticals, Inc. , announced today that it has closed its previously announced underwritten public offering of 700,000 shares of its 10.50% Series E Convertible Preferred Stock at a public … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboardSee who Peregrine is hiring next, click here to view […]

8:08 am Peregrine Pharma prices public offering of 700,000 shares of its 10.50% Series E Convertible Preferred Stock at $25.00 per share

moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboardSee who Peregrine is hiring next, click here to view […]

Peregrine Pharmaceuticals Prices Offering of Its Series E Preferred Stock

[Marketwired] – Peregrine Pharmaceuticals, Inc. , announced today that it has priced an underwritten public offering of 700,000 shares of its 10.50% Series E Convertible Preferred Stock at a public offering price of $25.00 … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboardSee who Peregrine is hiring next, click here to […]

Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2013 Financial Results and Recent Developments

[at noodls] – Meaningful Improvement in Median Overall Survival in Patients With Second-Line NSCLC Supports Advancing Bavituximab Into Phase III Development; Contract Manufacturing Revenue Tops $17 Million for Nine … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboardSee who Peregrine is hiring next, click here to view […]

Peregrine to Report Third Quarter Fiscal Year 2013 Financial Results After Market Close on March 12, 2013

[at noodls] – TUSTIN, CA — (Marketwire) — 03/05/13 — Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment … moreView todays social media effects on PPHMView the latest stocks trending across Twitter. Click to view dashboardSee who Peregrine is hiring next, click here to view […]